Study of Efient in ACS patients suggests new strategies needed
A study shows that pre-treatment with Efient/Effient (prasugrel hydrochloride), from Daiichi Sankyo and Eli Lilly, prior to catheterization, significantly increases the risk of life-threatening bleeding in Acute Coronary Syndrome patients, without reducing the risk of major ischemic events. The Phase III, randomized, double blind, event-driven ACCOAST study was conducted in Europe, Canada, Israel and Turkey and randomized 4033 patients to either pre-treatment with prasugrel or placebo.
For the primary endpoint, a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization or GPIIb/IIIa bailout at 7 and 30 days post-randomization, there was no significant difference between pre-treatment and no pre-treatment (10.0% vs 9.8%). Results suggests that there is no longer a need for pre-treatment in ACS patients to prevent ischemic complications while waiting for catheterization. Data was presented at ESC 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins